Tradewinds Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Tradewinds Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-500	Closed	-$3K	–	711
2018 Q3	$3K	Hold	500	–	–	﹤0.01%	557
2018 Q2	$2K	Hold	500	–	–	﹤0.01%	584
2018 Q1	$2K	Hold	500	–	–	﹤0.01%	588
2017 Q4	$3K	Hold	500	–	–	﹤0.01%	570
2017 Q3	$3K	Hold	500	–	–	﹤0.01%	556
2017 Q2	$4K	Hold	500	–	–	﹤0.01%	523
2017 Q1	$3K	Hold	500	–	–	﹤0.01%	564
2016 Q4	$4K	Hold	500	–	–	﹤0.01%	484
2016 Q3	$5K	Buy	+500	New	+$4.15K	﹤0.01%	444

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tradewinds Capital Management's PETX Position: Q4 2018 in Review

Tradewinds Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2018, closing a stake of 500 shares — an estimated $3K sold.

Tradewinds Capital Management first reported a position in PETX in Q3 2016 and held it in 9 quarters. The position peaked at $5K in Q3 2016. 115 funds tracked by Wall St. Rank hold PETX as of Q4 2018.

Tradewinds Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Tradewinds Capital Management sold 500 Aratana Therapeutics, Inc. shares in Q4 2018, an estimated $3K.
Tradewinds Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 9 quarters.
Tradewinds Capital Management's Aratana Therapeutics, Inc. position peaked at $5K in Q3 2016.
115 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2018.

Based on Tradewinds Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.